{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:43:37Z","timestamp":1790963017977,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s41030-020-00136-3","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T13:02:45Z","timestamp":1605618165000},"page":"101-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial"],"prefix":"10.1007","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct02164513","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"David M. G.","family":"Halpin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard J.","family":"Criner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Dransfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MeiLan K.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Elaine","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motokazu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Lettis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Lomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Lipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,17]]},"reference":[{"key":"136_CR1","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/S0140-6736(03)14865-9","volume":"362","author":"S Teramoto","year":"2003","unstructured":"Teramoto S, Yamamoto H, Yamaguchi Y, Matsuse T, Ouchi Y. Global burden of COPD in Japan and Asia. Lancet. 2003;362:1764\u20135.","journal-title":"Lancet"},{"key":"136_CR2","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020 Report. 2020. https:\/\/www.goldcopd.org\/. Accessed 5 Feb 2020."},{"key":"136_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5588\/ijtld.15.0472","volume":"20","author":"S Ehteshami-Afshar","year":"2016","unstructured":"Ehteshami-Afshar S, FitzGerald JM, Doyle-Waters MM, Sadatsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2016;20:11\u201323.","journal-title":"Int J Tuberc Lung Dis"},{"key":"136_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/resp.12660","volume":"21","author":"JL Lopez-Campos","year":"2016","unstructured":"Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21:14\u201323.","journal-title":"Respirology"},{"key":"136_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/j.1440-1843.2011.01982.x","volume":"16","author":"Y Fukuchi","year":"2011","unstructured":"Fukuchi Y, Fernandez L, Kuo HP, et al. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Respirology. 2011;16:825\u201335.","journal-title":"Respirology"},{"key":"136_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/COPD.S125058","volume":"12","author":"JA Wedzicha","year":"2017","unstructured":"Wedzicha JA, Zhong N, Ichinose M, et al. Indacaterol\/glycopyrronium versus salmeterol\/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. Int J Chron Obstruct Pulmon Dis. 2017;12:339\u201349.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"136_CR7","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.2147\/COPD.S110389","volume":"11","author":"M Ichinose","year":"2016","unstructured":"Ichinose M, Taniguchi H, Takizawa A, et al. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(\u00ae) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(\u00ae) studies. Int J Chron Obstruct Pulmon Dis. 2016;11:2017\u201327.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"136_CR8","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.2147\/COPD.S111408","volume":"11","author":"S Hashimoto","year":"2016","unstructured":"Hashimoto S, Ikeuchi H, Murata S, Kitawaki T, Ikeda K, Banerji D. Efficacy and safety of indacaterol\/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study. Int J Chron Obstruct Pulmon Dis. 2016;11:2543\u201351.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"136_CR9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1378\/chest.07-1131","volume":"133","author":"WC Tan","year":"2008","unstructured":"Tan WC, Ng TP. COPD in Asia: where East meets West. Chest. 2008;133:517\u201327.","journal-title":"Chest"},{"key":"136_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1440-1843.2004.00611.x","volume":"9","author":"K Tatsumi","year":"2004","unstructured":"Tatsumi K, Kasahara Y, Kurosu K, et al. Clinical phenotypes of COPD: results of a Japanese epidemiological survey. Respirology. 2004;9:331\u20136.","journal-title":"Respirology"},{"key":"136_CR11","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671\u201380.","journal-title":"N Engl J Med"},{"key":"136_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1183\/13993003.02165-2015","volume":"48","author":"SJ Pascoe","year":"2016","unstructured":"Pascoe SJ, Lipson DA, Locantore N, et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J. 2016;48:320\u201330.","journal-title":"Eur Respir J"},{"key":"136_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1513\/AnnalsATS.201409-413OC","volume":"12","author":"C Crim","year":"2015","unstructured":"Crim C, Dransfield MT, Bourbeau J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015;12:27\u201334.","journal-title":"Ann Am Thorac Soc"},{"key":"136_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1081\/COPD-200050513","volume":"2","author":"PW Jones","year":"2005","unstructured":"Jones PW. St George\u2019s respiratory questionnaire: MCID. COPD. 2005;2:75\u20139.","journal-title":"COPD"},{"key":"136_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.rmed.2017.07.060","volume":"131","author":"C Crim","year":"2017","unstructured":"Crim C, Calverley PMA, Anderson JA, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: the SUMMIT trial. Respir Med. 2017;131:27\u201334.","journal-title":"Respir Med"},{"key":"136_CR16","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.2147\/COPD.S165187","volume":"13","author":"T Ishii","year":"2018","unstructured":"Ishii T, Nishimura M, Akimoto A, James MH, Jones P. Understanding low COPD exacerbation rates in Japan: a review and comparison with other countries. Int J Chron Obstruct Pulmon Dis. 2018;13:3459\u201371.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"136_CR17","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1183\/09031936.00079409","volume":"35","author":"W Xu","year":"2010","unstructured":"Xu W, Collet JP, Shapiro S, et al. Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year. Eur Respir J. 2010;35:1022\u201330.","journal-title":"Eur Respir J"},{"key":"136_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12890-019-1000-x","volume":"20","author":"T Yang","year":"2020","unstructured":"Yang T, Cai B, Cao B, et al. REALizing and improving management of stable COPD in China: a multi-center, prospective, observational study to realize the current situation of COPD patients in China (REAL) - rationale, study design, and protocol. BMC Pulm Med. 2020;20:11.","journal-title":"BMC Pulm Med"},{"key":"136_CR19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/15412555.2018.1481022","volume":"15","author":"J Zheng","year":"2018","unstructured":"Zheng J, Zhong N, Wang C, et al. The efficacy and safety of once-daily fluticasone furoate\/umeclidinium\/vilanterol versus twice-daily budesonide\/formoterol in a subgroup of patients from China with symptomatic COPD at risk of exacerbations (FULFIL trial). COPD. 2018;15:334\u201340.","journal-title":"COPD"},{"key":"136_CR20","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.rmed.2012.04.008","volume":"106","author":"H Mullerova","year":"2012","unstructured":"Mullerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012;106:1124\u201333.","journal-title":"Respir Med"},{"key":"136_CR21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(04)15433-0","volume":"363","author":"A Berrington de Gonzalez","year":"2004","unstructured":"Berrington de Gonzalez A, Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet. 2004;363:345\u201351.","journal-title":"Lancet"},{"key":"136_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11604-018-0724-5","volume":"36","author":"KK Kumamaru","year":"2018","unstructured":"Kumamaru KK, Machitori A, Koba R, Ijichi S, Nakajima Y, Aoki S. Global and Japanese regional variations in radiologist potential workload for computed tomography and magnetic resonance imaging examinations. Jpn J Radiol. 2018;36:273\u201381.","journal-title":"Jpn J Radiol"},{"key":"136_CR23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1183\/09031936.00193908","volume":"34","author":"C Crim","year":"2009","unstructured":"Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34:641\u20137.","journal-title":"Eur Respir J"},{"key":"136_CR24","first-page":"CD010115","volume":"3","author":"KM Kew","year":"2014","unstructured":"Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;3:CD010115.","journal-title":"Cochrane Database Syst Rev"},{"key":"136_CR25","unstructured":"European Medicines Agency (EMA). Pharmacovigilance Risk Assessment Committee (PRAC), recommendation 2016. Inhaled corticosteroids (ICS) containing medicinal products indicated in the treatment of chronic obstructive pulmonary disease (COPD). 2016. https:\/\/www.ema.europa.eu\/medicines\/human\/referrals\/inhaled-corticosteroids-containing-medicinal-products-indicated-treatment-chronic-obstructive. Accessed 30 Sep 2020."},{"key":"136_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383:35\u201348.","journal-title":"N Engl J Med"},{"key":"136_CR27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1440-1843.2008.01415.x","volume":"14","author":"WC Tan","year":"2009","unstructured":"Tan WC, Seale P, Ip M, et al. Trends in COPD mortality and hospitalizations in countries and regions of Asia-Pacific. Respirology. 2009;14:90\u20137.","journal-title":"Respirology"},{"key":"136_CR28","doi-asserted-by":"publisher","first-page":"1900914","DOI":"10.1183\/13993003.00914-2019","volume":"54","author":"DMG Halpin","year":"2019","unstructured":"Halpin DMG, Celli BR, Criner GJ, et al. It is time for the world to take COPD seriously: a statement from the GOLD board of directors. Eur Respir J. 2019;54:1900914.","journal-title":"Eur Respir J"},{"key":"136_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/clpt.2008.141","volume":"84","author":"SU Yasuda","year":"2008","unstructured":"Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther. 2008;84:417\u201323.","journal-title":"Clin Pharmacol Ther"},{"key":"136_CR30","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.3399\/bjgp12X625120","volume":"62","author":"A Martin","year":"2012","unstructured":"Martin A, Badrick E, Mathur R, Hull S. Effect of ethnicity on the prevalence, severity, and management of COPD in general practice. Br J Gen Pract. 2012;62:e76-81.","journal-title":"Br J Gen Pract"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-020-00136-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-020-00136-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-020-00136-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T18:09:32Z","timestamp":1628618972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-020-00136-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["136"],"URL":"https:\/\/doi.org\/10.1007\/s41030-020-00136-3","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,17]]},"assertion":[{"value":"27 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}